The role of T-cell depletion (TCD) to prevent graftversus-host disease (GVHD) after matched unrelated donor allogeneic bone marrow transplant (MUD BMT) remains undefined. Most studies employ total body irradiation and pan TCD. Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD. The preparative regimen consisted of busulfan 14 mg/kg, cyclophosphamide 120 mg/kg and VP-16 50 mg/kg in all but one patient who only received busulfan and cyclophosphamide. Donor marrow was depleted of CD8 þ T cells by immunomagnetic bead separation. The patients were also treated with cyclosporine and methylprednisolone or FK-506 and mini-dose methotrexate. Four (15%) of 33 patients developed graft failure or rejection. However, three of these patients were serologically mismatched at HLA-Cw. Although 67% of evaluable patients developed acute GVHD, severe grade III-IV acute GVHD only developed in 19%. The severity of acute GVHD correlated with the degree of CD8 þ TCD. Median relapse-free survival was 5 months among 20 patients treated with active AML, and 28 months among 13 patients treated in complete remission. Our results confirm that MUD BMT with CD8 þ TCD for AML is a potentially curative treatment option.
For patients with advanced acute myelogenous leukemia (AML) who lack an HLA-matched sibling donor, a matched unrelated donor (MUD) allogeneic bone marrow transplant (BMT) offers an opportunity for cure. Unfortunately, MUD BMT is often complicated by potentially fatal, severe graft-versus-host disease (GVHD). 1, 2 Depleting the donor graft of T-cells may prevent GVHD. 3, 4 T-cell depletion (TCD) effectively prevents GVHD, but increases the risk of graft failure and leukemic relapse. 5, 6 One method of decreasing the risk of graft failure with TCD is to increase the immunosuppression of the preparative regimen. Thus, most preparative regimens for MUD BMT include total body irradiation (TBI). However, non-TBI-containing preparative regimens have been successfully utilized for MUD BMT. [7] [8] [9] Patients with AML may relapse after TCD BMT because this approach may not only prevent GVHD but may also prevent the graft-versus-leukemia (GVL) effect from developing. In an attempt to prevent GVHD, yet maintain GVL, several investigators have experimented with selective depletion of T-cell subsets. Early studies of CD8 þ TCD suggested a decrease in GVHD with no increase in relapse risk for patients transplanted with HLA-matched siblings. 10, 11 Indeed, a randomized trial of CD8 þ TCD vs unmanipulated marrow transplant from sibling donors demonstrated a reduction in the incidence of acute grade II-IV GVHD from 80 to 20% (P ¼ 0.004) with TCD, but no significant differences were seen in relapse risk or survival. 12 We developed a master protocol to assess the GVHD modulating effects of CD8 þ TCD with a non-TBIcontaining preparative regimen for the treatment of hematologic malignancy using MUD BMT. Each primary diagnosis had different accrual goals and study objectives. The targeted accrual goal of 30-40 AML patients has been met, thus we are reporting our AML experience. For AML, the primary study objective was to estimate relapse-free survival (RFS) and to compare overall survival to historical data. In addition, we planned to compare RFS between patients transplanted while in complete remission and those transplanted with active disease. Our hope was that selective TCD would reduce the incidence of severe GVHD without increasing the risk of relapse, particularly for patients transplanted in remission.
Methods and materials

Patients
All patients with AML receiving MUD BMT at the Cleveland Clinic Foundation were eligible for this study beginning in March 1993. The diagnosis of AML was made by histologic review of the initial diagnostic bone marrow aspirate specimen or by histologic and/or immunophenotypic analysis of subsequent blood or marrow specimens at the time of relapse. All patients had refractory, relapsed or secondary (transformed from an antecedent hematologic disorder) AML. All patients had normal hepatic, renal, pulmonary and cardiac function prior to treatment. Patients with a history of leukemic meningitis must have had normal spinal fluid cytology before MUD BMT. All patients were informed of the investigational nature of this study and signed an informed consent document approved by the Cleveland Clinic Foundation Institutional Review Board.
Preparative regimens
The first patient was treated with busulfan 16 mg/kg and cyclophosphamide 120 mg/kg (BuCy 2). 13 All other patients received a regimen consisting of busulfan 14 mg/kg, cyclophosphamide 120 mg/kg, and VP-16 50 mg/kg (BuCyVP).
14 Equine antithymocyte globulin (ATG) 30 mg/kg daily for 4 days beginning 3 days before transplant was added to BuCyVP in five patients who were receiving marrow transplants from donors mismatched at the HLA-C locus.
CD8 þ TCD
Donor marrow was harvested and delivered according to the standards set forth by the National Marrow Donor Program. From January 1993 through February 1996, the buffy coat was concentrated using a COBE 2991 (COBE Inc., Lakeland, CO, USA) cell processor. Mononuclear cells were separated by Ficoll-Hypaque gradient and the COBE 2991 cell processor. From January 1998 to present, the mononuclear cell preparation was performed directly from the marrow on a Baxter Fenwall CS 3000 Plus Blood Cell Separator (Baxter, Deerfield, IL, USA). Mononuclear cells were then adjusted to an approximate concentration of 20 Â 10 6 cells/ml. Dynabeads M-450 CD8 (Dynal, Oslo, Norway) were added to the mononuclear cells at a bead to target cell ratio of 4:1. The first marrow on this study was depleted with a 3:1 bead to target ratio. The cells and beads were incubated for 30 min at 2-61C, rotating end over end at 2 r.p.m. and then separated on the MaxSep Magnetic Cell Separator (Baxter, Deerfield, IL, USA) at a rate of 10 ml/min. The final CD8 þ T-cell-depleted marrow was centrifuged to remove excess volume and then immediately infused into the recipient.
Donor selection
Serologic typing for HLA-A, -B, -Cw, -DR, -DQ was performed by standard lymphocytotoxicity assays from peripheral blood samples. HLA-DRB1* and -DQB1* typing was performed by PCR-SSOP (sequence-specific oligonucleotide probing) or direct sequencing. For SSOP assays, extracted DNA was PCR amplified using exon 2 specific primers and hybridized with oligonucleotide probes obtained from commercial sources (Lifecodes Corporation, Stamford, CT, USA or One Lambda, Canoga Park, CA, USA) according to the manufacturer's instructions. Direct DRB1* exon 2 sequencing was performed using dyelabeled terminators (Applied Biosystems, Foster City, CA, USA) as previously described. 15 In cases performed since 1998, HLA-A*, B* and Cw* DNA-based typing was performed by PCR-SSP (sequence-specific priming) using commercial kits (Pel-Freez, Brown Deer, WI, USA), PCR-SSOP using oligonucleotide probes based on those used in the International Histocompatibility Workshops 16, 17 or commercial kits (One Lambda, Canoga Park, CA, USA) according to the manufacturer's instructions, or direct sequencing of exons 2 and 3 amplified products as described previously. 18 
GVHD prophylaxis
In addition to TCD, eight patients were treated with cyclosporine 3 mg/kg/day as a continuous intravenous (i. 
Supportive care
All patients were managed in a dedicated BMT unit in laminar airflow rooms with standard infection control procedures. All patients received G-CSF daily until neutrophil recovery beginning either the day after marrow infusion in patients not treated with prophylactic methotrexate or on day 12 after MUD BMT in patients treated with prophylactic methotrexate. All patients received weekly i.v. gammaglobulin while hospitalized, then at least monthly until 100 days after BMT.
Patient evaluation
Initial engraftment was defined as a sustained absolute neutrophil count (ANC) of greater than 500/ml. Graft failure was defined as failure to achieve an ANC greater than 500/ml. Graft rejection was defined as an unexplained, sustained decrease in the ANC to less than 500/ml after initial engraftment. Acute and chronic GVHD were diagnosed clinically with histologic confirmation whenever possible. Patients were followed from the day of transplant until pathologic evidence of leukemic relapse (RFS) and until death (overall survival).
Statistics
Survival and RFS were calculated from the date of BMT and were estimated using the method of Kaplan and Meier.
CD8 þ T-cell-depleted bone marrow transplantation for AML M Kalaycio et al RFS was estimated separately for patients who were transplanted while in complete remission and those who were transplanted with active disease and compared between groups using the log-rank test. The correlation of CD34 dose with days to neutrophil and platelet engraftment was assured using Spearman's rank correlation coefficient (r). The association of CD34 dose with survival was assessed using Cox's proportional hazards analysis. Among 27 patients who were evaluable for acute GVHD, the association of both CD8 þ and CD4 þ T-cell dose with acute GVHD was assessed using the Jonckheere-Terpstra test; for this analysis, acute GVHD was graded as 0, I, II, III or IV. A similar assessment was made for CD8 þ and CD4 þ T-cell dose with chronic GVHD among 18 patients who were evaluable for chronic GVHD; for this analysis, chronic GVHD was categorized as none, limited or extensive. All analyses were carried out using SAS s software; Po0.05 was used to indicate statistical significance.
Results
Patient characteristics
A total of 33 patients with AML were treated with CD8 þ TCD MUD BMT from March 1993 through June 2002. The characteristics of these patients are listed in Table 1 .
All patients in remission were in second or greater CR, except for one who was transplanted in first CR after failing two initial induction attempts and achieving CR with salvage chemotherapy. Four male patients received BMT from a female donor.
Donor/recipient HLA compatibility
Unrelated donors were identical to the recipient at HLA-A and -B by serology and identical at DRB1* at the DNA level by molecular typing in all but three cases (Table 1) . Whenever possible, Class I typing was confirmed by molecular methods. HLA-Cw was mismatched at one allele in nine cases.
CD8 þ TCD efficiency
The TCD process was very effective at depleting the marrow graft of CD8 þ T cells. The pre-and postdepletion cell doses are displayed in Table 2 . The predepletion cell dose was determined after the Ficoll-Hypaque step. The median dose of infused CD34 þ cells was reduced from 
Engraftment
Three patients died of transplant-related toxicity or infection before engraftment could be assessed. Of the 30 patients evaluable, four developed either graft failure or early (o2 months) graft rejection. Of the nine patients with a serologic HLA-Cw mismatch, three (33%) had graft failure or rejection compared to only one (5%) of the 21 matched at HLA-Cw. Of the five patients with HLA-Cw mismatches given ATG as part of the preparative regimen, two (40%) experienced graft failure or rejection. Salvage infusions of autologous non-T-cell-depleted stem cells resulted in hematopoietic recovery in three patients with graft failure or rejection.
The nine patients mismatched at HLA-Cw had a median infused CD34 þ cell dose of 1.64 Â 10 6 /kg (range 0.48-3.56) compared to a median dose of 2.09 Â 10 6 /kg (range 0.48-3.56) in the 24 patients matched at HLA-Cw (P ¼ 0.71).
The median time to neutrophil engraftment was 20 days (range 10-60). Only 18 patients engrafted platelets to 420 000/ml in a median time of 27 days (range 22-59). The CMV ¼ cytomegalovirus. a One patient had both an HLA-Cw and an HLA-A mismatch.
CD8 þ T-cell-depleted bone marrow transplantation for AML M Kalaycio et al other 12 patients died before platelet engraftment. Of the 18 patients engrafting platelets, 14 achieved a platelet count 4100 000/ml in a median of 82 days (range 38-280 days). There was no correlation between CD34 þ dose infused with days to neutrophil engraftment among 30 evaluable patients (r ¼ À0.17; P ¼ 0.37). Neither was there a correlation of dose with days to a platelet count 420 000/ml among 18 evaluable patients (r ¼ À0.19; P ¼ 0.45).
GVHD and treatment-related mortality
Only 27 patients were evaluable for acute GVHD. Four patients had graft failure and two died before GVHD could be assessed. Acute GVHD developed in 18 of these 27 patients (67%). However, grade III-IV GVHD only developed in five patients (19%). Of the 18 patients alive 100 days after BMT and therefore evaluable, 14 developed chronic GVHD (78%) that was extensive in seven (39%).
The dose of CD8 þ T cells correlated with the incidence and severity of acute and chronic GVHD ( Table 3 ). The median dose of CD8 þ cells was 0.16 Â 10 6 /kg in patients who did not get GVHD and was 0.40 Â 10 6 /kg in those who did (P ¼ 0.006). A higher infused CD8 þ T-cell dose was also associated with more severe acute (P ¼ 0.013) and chronic GVHD (P ¼ 0.016). CD4 þ T-cell dose was not associated with more severe acute (P ¼ 0.07) or chronic GVHD (P ¼ 0.12).
In all, 25 patients have died. Nonrelapse mortality accounted for 17 deaths. Seven patients died of GVHD, five died of infection, two died of hepatic veno-occlusive disease, and two died of multisystem organ failure or adult respiratory distress syndrome. One patient died as a result of graft failure and infection.
Relapse and survival
With a median follow-up of 37 months for surviving patients, eight have relapsed. Actuarial RFS at 3 years was 22%. However, for patients transplanted in remission, the estimated 3-year RFS was 45% compared to 0% for patients treated with active disease (Figure 1) . Indeed, the median RFS was only 5 months for patients treated with active disease, while patients in remission enjoyed a median RFS of 28 months. Nonetheless, two patients with active disease at the time of transplant remain alive in remission 17.8 and 18.7 months after transplant.
There was no association of CD34 þ cell dose with survival (hazard ratio ¼ 0.98; P ¼ 0.86).
Discussion
With standard GVHD prophylaxis, MUD BMT for AML causes severe, acute GVHD in approximately 50% of patients. 14, 19, 20 The application of TCD reduces the risk of severe, acute GVHD to approximately 25%. 4, [21] [22] [23] [24] Importantly, and in contrast to the case in chronic myelogenous leukemia, the reduction in the incidence of acute GVHD does not appear to substantially increase the risk of leukemic relapse in AML. 2, 3, 25, 26 Our data, indicating a risk of grade III-IV acute GVHD of 19% and an RFS of 45% at 3 years among patients treated in remission, confirm and extend these observations in a population of patients treated without TBI.
In contrast to other studies of CD8 þ TCD, we show an association of higher CD8 þ infusion cell dose with more severe acute and chronic GVHD. Other studies included patients with a variety of hematologic malignancies treated mostly with sibling donors. [10] [11] [12] Perhaps the association is only evident in patients with AML or in those at higher risk of GVHD, such as those treated with MUD BMT. However, our observation represents the first direct evidence that selective CD8 þ TCD effectively reduces the severity of GVHD by depleting the graft of CD8 þ cells. Given that our TCD process removed only about 2 logs of CD8 þ cells, more effective CD8 þ depletion techniques may improve results further.
Some studies of unmanipulated MUD BMT report rates of grade III-IV acute GVHD of less than 25%, similar to that reported after TCD MUD BMT. 23, [27] [28] [29] Indeed, preliminary data of a prospective, randomized trial of GVHD prophylaxis with TCD and CSP vs CSP and shortcourse methotrexate demonstrate no survival advantage for TCD. 30 However, these studies employ TBI in the suggest that cure is possible with MUD BMT for patients with refractory acute leukemia. 31 However, newer cytotoxic or biologic agents are needed before any improvement in cure rates is likely to be realized.
Bone marrow engrafts after MUD BMT in 90-100% of patients in the absence of TCD. 2, 27, 28, 32 Early reports that busulfan-based regimens are inadequate for engraftment of MUD bone marrow 33 have been disproved by several larger series indicating 88-100% engraftment. 9, 14, 34 Recent studies of TCD for MUD BMT report engraftment rates of 90-100% as well. 24, 35 We confirm the initial observation of Jansen et al 11 that busulfan-based regimens also result in reliable engraftment when combined with selective TCD.
Petersdorf et al 36 demonstrated the adverse effect of HLA-Cw mismatching on graft failure in the absence of TCD. Our graft failure rate of 15% can be attributed largely to the effect of serologic HLA-Cw mismatching. Despite the additional immunosuppression afforded by the addition of ATG in five our nine patients with HLA-Cw disparities, three failed to engraft. Only one of our 21 patients (5%) matched at HLA-C failed to engraft. Thus, HLA mismatching at HLA-Cw seems to increase the risk of graft failure in patients matched at other Class I antigens undergoing selective CD8 þ TCD.
Although the small number of patients in our study precludes definitive statements, there was no apparent difference in the median CD34 þ cell dose between those patients who were HLA-Cw matched and those who were not. This observation lends further support to our suspicion that HLA-Cw mismatching led to poor engraftment, not CD34 þ cell doses or lack of sufficient immunosuppression. Indeed, our engraftment rate is remarkable when one considers the low median CD34 þ dose infused following TCD and the preparative regimens employed. The infused dose has been correlated with engraftment and survival after MUD BMT in other studies. 6, 20 Although the small number of our patients analyzed may preclude statistical significance, there appear to be no such correlations within the small range of infused marrow doses in our study.
In summary, selective TCD MUD BMT offers those patients with relapsed AML without a sibling donor an opportunity for cure. Only prospective, randomized trials of this technique vs various alternatives can conclude superiority of one technique over another. However, given the scarcity of data for the treatment of single diagnoses with MUD BMT, our results help provide a starting point for the development of such trials for patients with relapsed or refractory AML.
